CEACAM1 and hepatocellular carcinoma: Interestingly, a recent using multimodal sequencing technologies (spatial transcriptomics, scRNA-seq, bulk RNA-seq, and TCR sequencing) in hepatocellular carcinoma (HCC) patients receiving neoadjuvant nivolumab identified a signaling axis involving UBASH3B/NR1I2/CEACAM1/HAVCR2, which mediates immunosuppressive interactions among tumor-associated macrophages (TAMs), tumor cells, and T cells, fostering a pro-tumorigenic environment and resistance to immune checkpoint blockade [70].